PMID- 31913152
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20210205
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Linking)
VI  - 27
IP  - 2
DP  - 2020 Mar
TI  - Recent advances in allogeneic hematopoietic cell transplantation for acute 
      myeloid leukemia.
PG  - 115-121
LID - 10.1097/MOH.0000000000000572 [doi]
AB  - PURPOSE OF REVIEW: Allogeneic hematopoietic cell transplantation (HCT), with 
      associated graft-versus-leukemia effects, remains the best postremission strategy 
      for patients with intermediate or high-risk acute myeloid leukemia (AML), with a 
      curative potential. Here, we highlight recent advances in allogeneic HCT that 
      broadened access, refined prognostication, and improved outcomes of AML patients 
      undergoing this procedure. RECENT FINDINGS: Eligibility for allogeneic HCT 
      continued to expand to AML patients older than 60 years, as well as to patients 
      lacking human leukocyte antigen (HLA)-matched donors with the advent of 
      alternative donor sources, such as umbilical cord blood and HLA-haploidentical 
      transplantation. Molecular profiling of AML has redefined prognostication for 
      patients in specific AML genomic subgroups undergoing allogeneic HCT and has 
      served as a new strategy for measuring minimal residual disease before and after 
      allogeneic HCT. Using high intensity conditioning regimens has emerged as a 
      potential strategy to reduce risk of relapse and improve overall survival, 
      especially in patients with minimal residual disease prior to allogeneic HCT. 
      SUMMARY: As access to allogeneic HCT continues to improve, also, with more 
      refined prognostic strategies, the field continues to move to optimize 
      transplantation approaches by decreasing the risk of relapse and minimizing 
      transplant-related complications.
FAU - Gomez-Arteaga, Alexandra
AU  - Gomez-Arteaga A
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center.
FAU - Gyurkocza, Boglarka
AU  - Gyurkocza B
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center.
AD  - Department of Medicine, Weill Cornell Medical College of Cornell University, New 
      York, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
SB  - IM
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*surgery
MH  - Transplantation Conditioning/*methods
EDAT- 2020/01/09 06:00
MHDA- 2020/06/04 06:00
CRDT- 2020/01/09 06:00
PHST- 2020/01/09 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2020/01/09 06:00 [entrez]
AID - 00062752-202003000-00011 [pii]
AID - 10.1097/MOH.0000000000000572 [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2020 Mar;27(2):115-121. doi: 10.1097/MOH.0000000000000572.